Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
1,944 results
  • New Antithrombotic Drugs in Acute Coronary Syndrome. [Review]
    J Clin Med. 2020 Jun 30; 9(7)Zwart B, Parker WAE, Storey RF
  • In recent years, much progress has been made in the field of antithrombotic drugs in acute coronary syndrome (ACS) treatment, as reflected by the introduction of the more potent P2Y12-inhibitors prasugrel and ticagrelor, and novel forms of concomitant anticoagulation, such as fondaparinux and bivalirudin. However, despite substantial improvements in contemporary ACS treatment, there remains resid…
  • Prophylaxis in nonorthopaedic surgery. [Review]
    Rev Clin Esp. 2020 Jun 03 [Online ahead of print]Pérez-Pinar M, Nieto-Rodríguez JA
  • Surgery increases the risk (by 20-fold) of venous thromboembolism (VTE), but there are prophylaxis methods (mechanical, pharmaceutical or combined) that safely reduce the incidence rate of VTE. The administration of prophylaxis requires a prior assessment of the risks associated with the patient and with the type of surgery. The Caprini and Rogers scales classify patients into four VTE risk categ…
  • Fondaparinux-Associated Rectus Sheath Hematoma: Skating on Thin Ice. [Case Reports]
    Cureus. 2020 May 02; 12(5):e7938.Sabanis N, Drylli A, … Zagkotsis G
  • Rectus sheath hematoma (RSH), an exceptionally rare clinical entity, results from the rupture of epigastric arteries or tear of the rectus abdominis muscle itself. Spontaneous RSH represents a potentially life-threatening bleeding complication in anticoagulated patients with distinct characteristics. The non-specific nature of RSH clinical manifestations renders RSH a kaleidoscopic disease that m…
  • Programmable One-Pot Synthesis of Heparin Pentasaccharide Fondaparinux. [Journal Article]
    Org Lett. 2020 Jun 04 [Online ahead of print]Dey S, Lo HJ, Wong CH
  • The clinically approved Fondaparinux (Arixtra) has been used for the treatment of deep vein thrombosis and acute pulmonary embolism since 2002 and is considered to be better than the low-molecular weight heparin in terms of anticoagulation response, duration of action, and biosafety. However, the synthetic methods previously developed for its manufacture are relatively complicated, thus restricti…
  • Glycosaminoglycans bind human IL-27 and regulate its activity. [Journal Article]
    Eur J Immunol. 2020 Jun 02 [Online ahead of print]Cavé MC, Maillard S, … Devergne O
  • IL-27 is a cytokine of the IL-12 family, composed of EBI3 and IL-27p28. IL-27 regulates immune responses and also other physiological processes including hematopoiesis, angiogenesis, and bone formation. Its receptor, composed of IL-27Rα and gp130, activates the STAT pathway. Here, we show that different glycosaminoglycans (GAGs) modulate human IL-27 activity in vitro. We find that soluble heparin…
  • Anti-Factor Xa Activity of Fixed-Dose Fondaparinux in Low-Body-Weight Patients With Acute Coronary Syndrome. [Journal Article]
    Ann Pharmacother. 2020 May 28 [Online ahead of print]Wongcharoen W, Tantisirivit N, … Phrommintikul A
  • Background: Fixed-dose 2.5 mg of fondaparinux subcutaneous injection once daily has been recommended in treatment of non-ST-segment elevation acute coronary syndrome (NSTE-ACS) irrespective of body weight (BW). However, data on anti-factor Xa (anti-FXa) activity of fondaparinux are scarce in low-BW patients. Objective: We aimed to assess anti-FXa activity of fondaparinux in low-BW patients (BW …
  • Management of acute pulmonary embolism 2019: what is new in the updated European guidelines? [Review]
    Intern Emerg Med. 2020 May 26 [Online ahead of print]Konstantinides S, Meyer G
  • Pulmonary embolism (PE) is the third most frequent acute cardiovascular syndrome. Annual PE incidence and PE-related mortality rates rise exponentially with age, and consequently, the disease burden imposed by PE on the society continues to rise as the population ages worldwide. Recently published landmark trials provided the basis for new or changed recommendations included in the 2019 update of…
  • [Heparin-Induced Thrombocytopenia after Total Knee Replacement]. [Case Reports]
    Acta Chir Orthop Traumatol Cech. 2020; 87(2):129-133.Salášek M, Šlechtová J, Pavelk T
  • Heparin-induced thrombocytopenia is a rare complication of treatment with both unfractionated heparin (UFH) and low molecular weight heparin (LMWH). Antibodies against the complex heparin-platelet factor 4 are the main cause of pathogenesis, resulting in the activation of thrombocytes, coagulation, endothelium, monocytes, neutrophils and subsequent highly prothrombotic state. The prothrombotic st…
  • Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey. [Journal Article]
    Oncologist. 2020 May 08 [Online ahead of print]Kakkar AK, Bauersachs R, … Levine M
  • CONCLUSIONS: Compared with the original FRONTLINE survey, FRONTLINE 2 reveals some differences in the management of VTE in patients with cancer. Newer anticoagulants such as fondaparinux, dabigatran, and rivaroxaban are being incorporated into the contemporary management of VTE in patients with cancer.This globally conducted survey of more than 5,000 cancer clinicians revealed a number of insights into the perceived risk for venous thromboembolism as well as contemporary approaches to its prevention and treatment. Although guidelines have consistently recommended anticoagulant medications for prevention and treatment of cancer-associated thrombosis, clinicians report substantial variation in their practice.
  • A "Catastrophic" Heparin-Induced Thrombocytopenia. [Case Reports]
    Case Rep Med. 2020; 2020:6985020.Barcellona D, Melis M, … Marongiu F
  • CONCLUSIONS: Patients presenting with HIT could show a very impressive thrombotic burden resembling to that of the catastrophic antiphospholipid syndrome. A careful differential diagnosis should be made towards other pathological conditions which lead to thrombocytopenia to avoid an unnecessary and potentially harmful platelet transfusion. Although fondaparinux is off-label, its use in patients with HIT is simple and seems to be effective.
  • Acute Coronary Syndrome: Management. [Journal Article]
    FP Essent. 2020 Mar; 490:20-28.Braun M, Kassop D
  • Aspirin is recommended for all patients with a suspected acute coronary syndrome (ACS) unless contraindicated. Addition of a second antiplatelet (ie, dual antiplatelet therapy) (eg, clopidogrel, ticagrelor, or prasugrel) also is recommended for most patients. Parenteral anticoagulation is recommended with unfractionated heparin, low-molecular-weight heparin, bivalirudin, and fondaparinux. Proton …
  • Glycosaminoglycans as Tools to Decipher the Platelet Tumor Cell Interaction: A Focus on P-Selectin. [Journal Article]
    Molecules. 2020 Feb 26; 25(5)Schwarz S, Gockel LM, … Schlesinger M
  • Tumor cell-platelet interactions are regarded as an initial crucial step in hematogenous metastasis. Platelets protect tumor cells from immune surveillance in the blood, mediate vascular arrest, facilitate tumor extravasation, growth, and finally angiogenesis in the metastatic foci. Tumor cells aggregate platelets in the bloodstream by activation of the plasmatic coagulation cascade and by direct…
  • The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis. [Journal Article]
    Blood Adv. 2020 Feb 25; 4(4):655-666.Naymagon L, Tremblay D, … Mascarenhas J
  • Guidelines currently favor vitamin K antagonists or low-molecular-weight heparins for treatment of noncirrhotic portal vein thrombosis (ncPVT). Use of direct oral anticoagulants (DOACs) in PVT has been met with concern because of the lack of data. We conducted a retrospective study to investigate the efficacy and safety of DOACs for the treatment of ncPVT, and to compare them with standard therap…
New Search Next